多发性硬化患者细胞特异性表观遗传年龄加速的评估
该病例对照研究利用既往独立研究的DNA甲基化数据,纳入583例多发性硬化患者和643名非多发性硬化对照,采用GrimAge算法计算表观遗传年龄加速。多发性硬化组的表观遗传年龄加速较对照组增加约9个月(95%CI 3.6-14.4),且该加速以B细胞依赖的方式与多发性硬化相关。
要点
- 多发性硬化患者整体表观遗传年龄加速较对照增加约9个月(95%CI 3.6-14.4)。
- 表观遗传年龄加速与多发性硬化以B细胞依赖方式相关(βint=1.7,95%CI 0.3-2.8)。
- 在富集B细胞的验证数据集中,多发性硬化患者表观遗传年龄加速较对照增加5.1年(95%CI 2.8-7.4)。
核心结论
- 本研究提供有力证据表明多发性硬化中B细胞表现出显著的表观遗传年龄加速,支持B细胞过早免疫衰老参与多发性硬化发病的假说。
- 作者认为未来多发性硬化研究应关注B细胞中与年龄相关的分子机制。
研究设计与样本
- 病例对照研究,利用多个既往独立发表的DNA甲基化数据,纳入583例多发性硬化患者和643名非多发性硬化对照,并进行多因素统计建模。
- 使用来自3个独立数据集的细胞分选DNA甲基化数据进行验证。
主要发现
- 多发性硬化组表观遗传年龄加速较对照组增加约9个月(95%CI 3.6-14.4,p=0.001)。
- 统计解卷积显示表观遗传年龄加速与多发性硬化以B细胞依赖方式相关(βint=1.7,95%CI 0.3-2.8,p=0.002),与B细胞比例无关。
- 在富集B细胞的3个独立验证数据集中,多发性硬化患者表观遗传年龄加速较对照增加5.1年(95%CI 2.8-7.4,p=5.5×10-5)。
- 在富集T细胞的数据集中,多发性硬化患者与对照间表观遗传年龄加速无差异。
- 表观遗传年龄加速归因于β2微球蛋白的DNA甲基化替代标志物(差值=47,546,95%CI 10,067-85,026,p=7.2×10-5)和吸烟包年数(差值=8.1,95%CI 1.9-14.2,p=0.002)。
临床怎么用
- 原文未据此给出临床推荐,作者认为未来多发性硬化研究应关注B细胞中与年龄相关的分子机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In multiple sclerosis (MS), accelerated aging of the immune system (immunosenescence) may be associated with disease onset or drive progression. DNA methylation (DNAm) is an epigenetic factor that varies among lymphocyte subtypes, and cell-specific DNAm is associated with MS. DNAm varies across the life span and can be used to accurately estimate biological age acceleration, which has been linked to a range of morbidities. The objective of this study was to test for cell-specific epigenetic age acceleration (EAA) in people with MS. METHODS: This was a case-control study of EAA using existing DNAm data from several independent previously published studies. Data were included if .idat files from Illumina 450K or EPIC arrays were available for both a case with MS and an age-matched and sex-matched control, from the same study. Multifactor statistical modeling was performed to assess the primary outcome of EAA. We explored the relationship of EAA and MS, including interaction terms to identify immune cell-specific effects. Cell-sorted DNA methylation data from 3 independent datasets were used to validate findings. RESULTS: We used whole blood DNA methylation data from 583 cases with MS and 643 non-MS controls to calculate EAA using the GrimAge algorithm. The MS group exhibited an increased EAA compared with controls (approximately 9 mths, 95% CI 3.6-14.4), p = 0.001). Statistical deconvolution showed that EAA is associated with MS in a B cell-dependent manner (β int = 1.7, 95% CI 0.3-2.8), p = 0.002), irrespective of B-cell proportions. Validation analysis using 3 independent datasets enriched for B cells showed an EAA increase of 5.1 years in cases with MS compared with that in controls (95% CI 2.8-7.4, p = 5.5 × 10-5). By comparison, there was no EAA difference in MS in a T cell-enriched dataset. We found that EAA was attributed to the DNAm surrogates for Beta-2-microglobulin (difference = 47,546, 95% CI 10,067-85,026; p = 7.2 × 10-5), and smoking pack-years (difference = 8.1, 95% CI 1.9-14.2, p = 0.002). DISCUSSION: This study provides compelling evidence that B cells exhibit marked EAA in MS and supports the hypothesis that premature B-cell immune senescence plays a role in MS. Future MS studies should focus on age-related molecular mechanisms in B cells.
引用
- Maltby V, Xavier A, Ewing E, et al. Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis. Neurology. 2023. PMID: 37541839. doi:10.1212/WNL.0000000000207489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。